NRIX · available-data snapshot
Nurix Therapeutics, Inc. (NRIX): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Nurix Therapeutics, Inc. (NRIX); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for NRIX?
We do not publish a fair value for Nurix Therapeutics, Inc.. What we can say from its filings and market data is below.
What is NRIX's TickerWorth Score?
Scores higher than most companies we compare it with
Compared with Healthcare companies in US
Its strongest point: looks cheap on the numbers.
our cash-flow model doesn't fit this business, so we won't award our top grade off the remaining lenses
- Value · 82 of 100
Cheaper than 82% of Healthcare companies in US
- Price vs worth · 100 of 100
- Quality · 82 of 100
More profitable than 82% of Healthcare companies in US
- Financial health · 94 of 100
Financially stronger than 94% of Healthcare companies in US
- Growth · 100 of 100
Growing faster than virtually every one of the Healthcare companies in US
- Momentum · 72 of 100
Outperformed 72% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $25.02
- Market cap
- $2,
733, 430, 528 - 52-week high
- $28.23
- 52-week low
- $9.93
- Currency
- USD
- Exchange
- NasdaqGM
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Nurix Therapeutics, Inc. (NRIX) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, NRIX trades at a recent price of $25.02, a market capitalisation of about $2,733,430,528, sitting 82% of the way up its 52-week range ($9.93–$28.23), on the NasdaqGM.
The standard alternative to a DCF is relative valuation — comparing NRIX's trading multiples against a sector benchmark. Here that gives P/E of 10.3× (cheaper than the peer median of 42.2×); P/B of 2.8× (cheaper than the peer median of 7.9×); P/S of 3.9× (cheaper than the peer median of 6.2×); EV/EBITDA of 5.7× (cheaper than the peer median of 18.5×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. NRIX shows a price-to-book (P/B) of 2.82 and book value of $8.87 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. NRIX is in a mixed trend, trading -11.4% from its 52-week high. Over the past year the stock is +135.0%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
NRIX vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | NRIX | Peer median | Read |
|---|---|---|---|
| P/E | 10.3× | 42.2× | cheaper than |
| P/B | 2.8× | 7.9× | cheaper than |
| P/S | 3.9× | 6.2× | cheaper than |
| EV/EBITDA | 5.7× | 18.5× | cheaper than |
What does Nurix Therapeutics, Inc. do?
What does it do?
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 317 people.
How does it make money?
The business turns $702M in annual revenue into profit. Out of every $100 of sales, about $83 is left as operating profit (operating margin of 83.1%), after a 52% gross margin on the products/services it sells. After all costs, taxes and interest, 42.0% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: carries modest debt (0.1× equity), comfortably covers its short-term bills (8.4× current ratio), and is currently profitable.
Who at NRIX filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Hansen Gwenn | Chief Scientific Officer | Option exercise | $2,700.72 | Form 4 for Hansen Gwenn (opens sec.gov in a new tab) | |
| Hansen Gwenn | Chief Scientific Officer | Open-market sale | $36,300.00 | Form 4 for Hansen Gwenn (opens sec.gov in a new tab) | |
| GREGORY JULIA P | Director | Option exercise | $42,004.38 | Form 4 for GREGORY JULIA P (opens sec.gov in a new tab) | |
| GREGORY JULIA P | Director | Open-market sale | $528,528.02 | Form 4 for GREGORY JULIA P (opens sec.gov in a new tab) | |
| Ring Christine | Chief Legal Officer | Option exercise | $50,453.92 | Form 4 for Ring Christine (opens sec.gov in a new tab) | |
| Ring Christine | Chief Legal Officer | Open-market sale | $134,148.99 | Form 4 for Ring Christine (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.